iLink (Incentives for Linkage to ART) Study: A Mixed-methods Study to Improve Linkage to HIV Care (iLink)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02440386 |
Recruitment Status : Unknown
Verified October 2016 by Brendan Maughan-Brown, University of Cape Town.
Recruitment status was: Active, not recruiting
First Posted : May 12, 2015
Last Update Posted : October 17, 2016
|
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
HIV | Behavioral: Conditional economic incentive | Not Applicable |

Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 87 participants |
Allocation: | Randomized |
Intervention Model: | Single Group Assignment |
Masking: | Single (Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | iLink (Incentives for Linkage to ART) Study: A Mixed-methods Study to Improve Linkage to HIV Care |
Study Start Date : | April 2015 |
Actual Primary Completion Date : | July 2016 |
Estimated Study Completion Date : | November 2016 |
Arm | Intervention/treatment |
---|---|
No Intervention: Control
The control arm receives standard of care. Standard of care involves referral for ART services and follow-up calls (maximum of 6) to assess whether linkage to care has occurred.
|
|
Experimental: Incentive
The incentive arm receives standard of care plus a R300 voucher. The R300 voucher can be exchanged for cash if the participant starts ART at any clinic of their choice within three months from study enrollment.
|
Behavioral: Conditional economic incentive
Individuals in the intervention arm will receive the standard of care. In addition, individuals in the intervention arm receive a voucher worth R300. They are told that they will get this money if they:
Other Name: CEI |
- ART initiation [ Time Frame: 3 months ]Commencement of antiretroviral therapy for HIV
- Time to ART initiation [ Time Frame: 1-52 weeks ]Days between referral for ART and ART initiation
- Linkage to Care: first visit to clinic [ Time Frame: 3 months ]Self-reported attendance at an HIV/ART clinic within 3 months of study enrollment
- Time to linkage to care [ Time Frame: 1-52 weeks ]Days between referral for ART and attendance at an HIV/ART clinic
- ART retention [ Time Frame: 12 months ]Indicator of whether the participant collected his/her ART 1 year after starting treatment
- Feasibility - accrual percentage [ Time Frame: 6 months ]Number of people enrolled in study/number approached for enrollment
- Feasibility - participant tracking [ Time Frame: 3 and 6 months post enrolment ]Number of participants contact at 3 and 6 months/number of participants enrolled
- Acceptability - adverse events [ Time Frame: 6 months ]Unexpected risks/harms of providing incentives as self-reported by participants

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Referred for ART by the Tutu Tester Mobile Clinic (CD4 ≤ 500 or WHO stage 4)
- Planning to live in the study area for the next 6 months
- Willing and able to provide written informed consent for study participation
- Willing to accept calls from the study staff
Exclusion Criteria:
- Participated in the study previously
- Previously been on ART
- Intoxicated at the time of enrolment

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02440386
South Africa | |
Tutu Tester Mobile Clinic, Desmond Tutu HIV Foundation | |
Cape Town, Western Cape, South Africa, 7705 |
Principal Investigator: | Brendan Maughan-Brown, PhD | University of Cape Town | |
Principal Investigator: | Omar Galarraga, PhD | Brown University |
Responsible Party: | Brendan Maughan-Brown, Dr, University of Cape Town |
ClinicalTrials.gov Identifier: | NCT02440386 History of Changes |
Other Study ID Numbers: |
HRECREF:849/2014 |
First Posted: | May 12, 2015 Key Record Dates |
Last Update Posted: | October 17, 2016 |
Last Verified: | October 2016 |